Is Magnesium a marker of disordered mineral metabolism in males with idiopathic recurrent calcium urolithiasis? Observations focussing on fasting magnesiuria and magnesiemia, protein and other substances in urine and plasma

Magnesium Research

Volumn 16, Issue 3, 2003, Pages 192-205

  Schmiedl, Angelika ^a   Schwille, Paul Otto ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b NONE   (Germany)

Author keywords

Acid base status; Blood; Calcium Phosphorus; Insulin and glucose; Magnesium; Natriuresis; Plasma; Proteinuria; Renal calcium stones; Urine

Indexed keywords

BICARBONATE; BIOLOGICAL MARKER; CALCIUM; CALCIUM OXALATE; CALCIUM PHOSPHATE; CITRIC ACID; GLUCOSE; HYDROXYAPATITE; INSULIN; MAGNESIUM; OXALIC ACID; PARATHYROID HORMONE; PHOSPHATE; SODIUM;

ADULT; AGED; ARTICLE; BICARBONATE BLOOD LEVEL; BODY WEIGHT; CALCIUM EXCRETION; CALCIUM STONE; CONTROLLED STUDY; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCALCIURIA; IDIOPATHIC DISEASE; INSULIN BLOOD LEVEL; MAGNESIUM BLOOD LEVEL; MAGNESIUM EXCRETION; MAGNESIUM URINE LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MINERAL METABOLISM; NEPHROLITHIASIS; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PH; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RECURRENT DISEASE; SODIUM EXCRETION; URINARY EXCRETION; URINE LEVEL; URINE PH; UROLITHIASIS;

BIOLOGICAL MARKERS; BLOOD PROTEINS; CALCIUM; FASTING; HUMANS; MAGNESIUM; MALE; MIDDLE AGED; PHOSPHORUS; PROTEINURIA; URINARY CALCULI;

URIA;

EID: 0242657387     PISSN: 09531424     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Sutton R.A.L., Domrangkitchchaiborn S. Abnormal renal magnesium handling. Min Electrolyte Metab 1993; 19, 232-40.
2. Schmiedl A., Schwille P.O., Bergé B., Markovic M., Dvorak O. Reappraisal of the quantity and nature of renal calcifications and mineral metabolism in the magnesium-deficient rat. Urol Int 1998; 61, 76-85.
3. Durlach J. (1992): Magnesium in der klinischen Praxis; Stuttgart, Jena G. Fischer.
4. Resnick L.M., Altura B.T., Gupta R.K., Laragh J.H., Alderman M.H., Altura B.M. Intracellular and extracellular magnesium depletion in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993; 36, 767-70.
5. Schwille P.O., Schmiedl A., Herrmann U., Fan J., Gottlieb D., Manoharan M., Wipplinger J. Magnesium, citrate, magnesium citrate and magnesium-alkali citrate as modulators of calcium oxalate crystallization in urine: observations in patients with recurrent idiopathic calcium urolithiasis. Urol Res 1999; 27, 117-26.
6. Ettinger B., Pak C.Y.C., Citron J.T., Thomas C., Adams-Huet B., Vangessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 1997; 158, 2069-73.
7. Takeuchi H., Yoshida O. (1989): Magnesium and urinary stones. In: Magnesium in health and disease, eds Y. Itokawa, J. Durlach, pp. 377-82, London, Paris: John Libbey.
8. Schmiedl A., Schwille P.O. Magnesium status in idiopathic calcium urolithiasis - An orientational study in younger males. Eur J Clin Chem Clin Biochem 1996; 34, 393-400.
9. Khan S.R. Tubular cell surface events during nephrolithiasis. Curr Op in Urol 1997; 7, 240-247.
10. Kok D.J. Intratubular crystallization events. World J Urol 1997; 15, 219-28.
11. Doyle I.R., Ryall R.L., Marshall V.R. Inclusion of proteins into calcium oxalate crystals precipitated from human urine: a highly selective phenomenon. Clin Chem 1991; 37, 1589-94.
12. Dussol P., Geider S., Lilova A., Léonetti F., Dupuy P., Daudon M., Berland Y., Dagorn J.C., Verdier J.M. Analysis of the soluble organic matrix of five morphologically different stones. Urol Res 1995; 23, 45-51.
13. Larsson L., Sörbo B., Tiselius H.G., Öhmann S. A method for quantitative wet-chemical analysis of urinary calculi. Clin Chim Acta 1984; 140, 9-13.
14. Herrmann U., Schwille P.O., Kuch P. Crystalluria determined by polarization microscopy. Urol Res 1990; 19, 151-58.
15. Green J. (1996): The role of bone in the maintenance of acid-base homeostasis: Cellular and non-cellular factors. In. Kidney Stones, eds F.L. Coe, M.J. Farus, C.Y.C. Pak, J.H. Parks, G.M. Preminger, pp. 821-49. Philadelphia: Medical and Surgical management Lippincott-Raven Publishers.
16. Manoharan M., Schwille P.O. Oxypurines, protein, glucose and the functional state of blood vasculature are markers of renal recurrent calcium stone-forming processes? Observations in men with idiopathic recurrent calcium urolithiasis. Clin Chem Lab Med 2002; 40, 266-77.
17. Ryan M.F. The role of magnesium in clinical biochemistry: an overview. Ann Clin Biochem 1991; 28, 19-26.
18. Rosolova H., Mayer jr. O., Reaven G.M. Insulin-mediated glucose disposal is decreased in normal subjects with relatively low plasma magnesium concentration. Metab 2000; 49, 418-20.
19. Schwille P.O., Schmiedl A., Manoharan M. (manuscript in preparation): Calcium oxalate and calcium phosphate nucleation in postprandial urine of males with idiopathic calcium urolithiasis are related to associated free citrate and protein? An observational study indicating co-precipitation and a modulating role of urine pH.
20. Schwille P.O., Rümenapf G. (1990): Idiopathic calcium urolithiasis - Clinical problems and suggested approaches in an ambulatory stone clinic. In: Renal Tract Stone, eds J.E.A. Wickham, A. Buck, pp 217-238. Edinburgh, London, Melbourne, New York: Metabolic Basis and Clinical Practice - Churchill Livingstone.
21. Robertson W.G., Marshall R.W. Ionized calcium in body fluids. CRC Crit Rev Clin Lab Sci 1981; 15, 85-125.
22. Chen P.S., Toribara T.Y., Warnre H. Microdetermination of phosphorus. Anal Chem 1956; 28, 1756-1760.
23. Solini A., De Fronzo R. Insulin resistance, hypertension and cellular ion transport. Acta Diabetol 1992; 29, 196-200.
24. Manoharan M., Schwille P.O. Measurement of oxalate in human plasma ultrafiltrate by ion chromatography. J Chromatogr B 1997; 700, 261-8.
25. Werness P.G., Brown C.M., Smith L.H. EQUIL-2: a BASIC computer program for the calculation of urinary saturation. J Urol 1985; 134, 1242.
26. Finlayson B., Khan S.R., Hackett R. (1990): Theoretical chemical models of urinary stones. In: Renal Tract Stone, eds J.E.A. Wickham, A.C. Buck, pp. 133-147. Edinburgh, London, Melbourne, New York: Metabolic Basis and Clinical Practice - Churchill Livingstone.
27. Ginn H.E., Shanbour L.L. Phosphaturia in magnesium-deficient rats. Am J Physiol 1967; 212, 1347-50.
28. Petrault I., Zimowska W., Mathieu J., Bayle D., Rock E., Favier A., Rayssiguer Y., Mazur A. Changes in gene expression in rat thymocytes identified by cDNA support the occurrence of oxidative stress in early magnesium deficiency. Biochim Biophys Acta 2002; 1586, 92-8.
29. Scholz D., Schwille P.O., Sigel A. Ernährungsgewohnheiten von Patienten mit Urolithiasis. Fortschr Urol Nephrol 1981; 17, 83-6.
30. Gambaro G., Marchini F., Budakovic A., Checchetto S., Baggio B. Genetic approach to the study of cellular ion transport anomalies in idiopathic calcium nephrolithiasis. Contrib Nephrol 1997; 122, 189-92.
31. Schimatschek H.F., Rempis R. Prevalence of hypomagnesemia in an unselected German population of 16000 individuals. Magnes Res 2001; 14, 283-90.
32. Sutton R.A.L. Renal handling of calcium and magnesium in idiopathic stone disease. Contr Nephrol 1987; 58, 93-100.
33. Barnes B.A., Cope O., Harrison T. Magnesium conservation in the human being on a low magnesium diet. J Clin Invest 1958; 37, 430-40.
34. De Fronzo R.A., Bonadonna R.C., Ferannini E. Pathogenesis of NIDDM. Diabet Care 1992; 15, 318-68.
35. Wälthi M.K., Zimmermann M.B., Spinas G.A., Jacob S., Hurell R.F. Dietary magnesium intake in type 2 diabetes. Eur J Clin Nutr 2002; 56, 409-14.
36. Schwille P.O., Schmiedl A., Herrmann U., Wipplinger J. Postprandial hyperinsulinemia, insulin resistance and inappropriately high phosphaturia are features of younger males with idiopathic calcium urolithiasis; attenuation by ascorbic acid supplementation of a test meal. Urol Res 1997; 25, 49-58.
37. Flessa P., Tosco C., Paganin L., Mioni G., Zattoni F., Guerra U.P. (1999): Insulin sensitivity and arterial blood pressure in stone formers. In: Kidney Stones, eds L. Borghi, T. Meschi, A. Briganti, T. Schianchi, A. Novarini, pp. 603-5. Cosenza: Editoriale Bios.
38. Linda Kao W.H., Folsom A.R., Nieto J., Jing-Ping M.O., Watson R.L., Brancati FL. Serum and dietary magnesium and the risk for type 2 diabetes mellitus. Arch Int Med 1999; 159, 2151-9.
39. Schmiedl A., Schwille P.O. (1999): Dietary sodium retention and urinary calcium loss in idiopathic calcium urolithiasis (ICU). Correction by a test meal supplemented with alkalinizing magnesium citrate. In: Kidney Stones, eds L. Borghi, T. Meschi, A. Briganti, T. Schianchi, A. Novarini, pp. 561-3. Cosenza: Editoriale Bios.
40. Rivera R., Soldati L., Manunta P., Zerbi S., Adamo D., Bianchi G., Vezzoli G. (1999): Role of plasma circulating ouabain-like factor in idiopathic hypercalciuria. In: Kidney Stones, eds L. Borghi, T. Meschi, A. Briganti, T. Schianchi, A. Novarini, pp. 481-3. Cosenza: Editoriale Bios.
41. Halabe A., Wong N.L., Wong E.F., Sutton R.A. Atrial natriuretic factor levels in renal stone patients with idiopathic hypercalciuria and in healthy controls: The effect of an oral calcium load. Metab 1990; 39, 209-212.
42. Bergstrom W.H., Wallace W.M. Bone as a sodium and potassium reservoir. J Clin Invest 1954; 33, 867-73.
43. Walser M. (1973): Divalent cations: physicochemical state in glomerular filtrate and urine, and renal excretion. In: Handbook of Physiology, Section 8, eds J. Orloff, R.W. Berliner, pp 555-586. Washington DC: American Physiological Society.
44. Biber J., Murer H., Forster I. The renal type II Na + /Phosphate cotransporter. J Bioenerget Biomembr 1998; 30, 187-94.
45. Schwille P.O., Schlenk I., Samberger N.M., Bornhof C. Fasting urine excretion of magnesium, calcium and sodium in patients with renal calcium stones. Urol Res 1976; 4, 33-43.
46. Schwille P.O., Herrmann U., Schmiedl A., Kissler H., Wipplinger J., Manoharan M. Urinary phosphate excretion in the pathophysiology of idiopathic recurrent calcium urolithiasis: hormonal interactions and lipid metabolism. Urol Res 1997; 25, 417-26.
47. Kinne-Safran E. Renal H + -ATPases. Ann NY Acad Sci 1989; 574, 189-203.
48. Mizgala C.L., Quamme G.A. Renal handling of phosphate. Physiol Rev 1985; 65, 431-66.
49. Alpern R.J., Sakhae K. The clinical spectrum of chronic metabolic acidosis: homeostatic mechanisms produce significant morbidity. Am J Kidney Dis 1997; 29, 291-302.
50. Hunter G.K., Hauschka P.V., Poole A.V., Rosenberg L.C., Goldberg H.A. Nucleation and inhibition of hydroxyapatite formation by mineralized tissue protein. Biochem J 1996; 317, 59-64.
51. Takahiro Y., Sato M., Fujita K., Tozawa K., Nomura S., Kohri K. Effects of citrate on renal stone formation and osteopontin expression in a rat urolithiasis model. Urol Res 2001; 29, 50-56.
52. Hess B., Nakagawa Y., Parks J.H., Coc F.L. Molecular abnormality of Tamm-Horsfall glycoprotein in calcium oxalate nephrolithiasis. Am J Physiol 1991; 260, F 569-F 578.
53. Prié D., Ravery V., Baccon-Gibod L., Friedlander G. Frequency of renal phosphate leak among patients with calcium nephrolithiasis. Kidney Int 2001; 60, 272-6.
54. Tosukowong P., Borronpadungkitti S, Prasongwatana V., Tungsanga P., Jutuporn S., Dissayabutr T., Reungjui S., Sriboonlue P. Urinary citrate excretion in patients with renal stone: roles of leucocyte ATP citrate lyase activity and potassium salts therapy. Clin Chim Acta 2002; 325, 71-8.
55. Ryall R.L., Marshall V.R. (1990): The investigation and management of idiopathic urolithiasis. In: Renal Tract Stone, eds J.E.A. Wickham, A.C. Buck, pp. 307-331. Edinburgh, London, Melbourne, New York: Metabolic Basis and Clinical Practice -Churchill Livingstone.